EXPD vs GPN

EXPD exhibits exceptional operational health with a Piotroski F-Score of 8/9 and a very conservative debt profile (Debt/Equity 0.24). However, the stock is severely overvalued, trading at $147.56—nearly 3x its Graham Number ($48.53) and 3.5x its Intrinsic Value ($41.65). This valuation gap is exacerbated by negative YoY revenue (-3.30%) and earnings growth (-11.50%), alongside a high PEG ratio of 3.80. With bearish insider selling and a 0/100 technical trend, the current price appears unsustainable relative to fundamental growth.

GPN presents a stark contrast between strong deterministic health and deteriorating growth. While the Piotroski F-Score of 7/9 indicates robust financial health and the stock trades significantly below its Graham Number ($98.18) and book value (P/B 0.71), these value metrics are countered by a severe collapse in earnings growth (-59.20% YoY) and a bearish technical trend (0/100). The massive discrepancy between the current P/E (15.42) and Forward P/E (4.22) suggests the market is pricing in a recovery that is not yet evident in the quarterly data. Consequently, the stock appears to be a deep-value play with significant execution risk.